LEXINGTON, MA – Biotech company Quanterix announced today its ambitious plan to achieve between $169 million and $174 million in revenue by 2026, a forecast so meticulously calculated it reportedly includes the precise value of forgotten coffee machine change. The company attributes this remarkably specific financial prophecy to a renewed focus on 'diagnostics' and, more crucially, 'cost synergies' – a term analysts confirm is legally required to appear in all forward-looking statements.

“We’ve identified numerous opportunities to synergize our diagnostic capabilities,” stated CEO Kevin Hrusovsky in a press release that was 80% buzzwords and 20% legal disclaimers. “This includes optimizing our operational efficiencies, leveraging our core competencies, and, frankly, just picking up all the loose pennies we’ve been ignoring.” He added that the company’s new “Loose Penny Task Force” is expected to contribute significantly to the lower end of the revenue target.

Industry observers were quick to praise the company’s transparency. “Most companies just say ‘growth’ or ‘increased shareholder value’,” noted market analyst Brenda Chen. “Quanterix has given us a five-million-dollar window three years out. That’s either visionary or they’ve got a really good dartboard.” The company also hinted at future plans to synergize its synergies, promising even more precise revenue targets for 2027.

Sources close to the company suggest the upper end of the revenue target includes projected earnings from a new line of branded diagnostic-themed office supplies.